Discover
PYXS
Pyxis Oncology, Inc.
3.33
2 x 2.44
2 x 4.31
bid
ask
-
0.08
2.35%
2 @ 07:54 PM
3.33 +0.00 (0.00%)
| Ytd | 189.57% | |
| 1y | 43.53% |
3.33
day range
3.44
1.06
52 week range
5.34
| Open | 3.38 | Prev Close | 3.41 | Low | 3.33 | High | 3.44 | Mkt Cap | 277.75M |
| Vol | 564.35K | Avg Vol | 1.34M | EPS | -1.40 | P/E | N/A | Forward P/E | -1.40 |
| Beta | 1.28 | Short Ratio | 3.13 | Inst. Own | 56.55% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-02 | 50-d Avg | 3.06 | 200-d Avg | 2.21 | 1yr Est | 10.00 |
| Income Statement | |||
| Operating Expenses | 25.99M | ||
| Research and Development Expense | 16.06M | ||
| Selling, General and Administrative Expense | 9.93M | ||
| Operating Income | -25.99M | ||
| Net Income | -25.35M | ||
| Net Income Common Stock | -25.35M | ||
| Net Income Common Stock (USD) | -25.35M | ||
| Consolidated Income | -25.35M | ||
| Earnings per Basic Share | -0.40 | ||
| Earnings per Basic Share (USD) | -0.40 | ||
| Earnings per Diluted Share | -0.40 | ||
| Earning Before Interest & Taxes (EBIT) | -25.35M | ||
| Earning Before Interest & Taxes (USD) | -25.35M | ||
| Weighted Average Shares | 63.99M | ||
| Weighted Average Shares Diluted | 63.99M | ||
| Balance Sheet | |||
| Cash and Equivalents | 20.33M | ||
| Cash and Equivalents (USD) | 20.33M | ||
| Investments | 14.14M | ||
| Investments Current | 14.14M | ||
| Current Assets | 36.73M | ||
| Property, Plant & Equipment Net | 18.19M | ||
| Total Assets | 54.92M | ||
| Debt Current | 1.82M | ||
| Total Debt | 17.83M | ||
| Current Liabilities | 27.47M | ||
| Debt Non-Current | 16.01M | ||
| Total Liabilities | 43.48M | ||
| Accumulated Retained Earnings (Deficit) | -491.79M | ||
| Accumulated Other Comprehensive Income | -4.00K | ||
| Shareholders Equity | 11.44M | ||
| Shareholders Equity (USD) | 11.44M | ||
| Assets Non-Current | 18.19M | ||
| Total Debt (USD) | 17.83M | ||
| Liabilities Non-Current | 16.01M | ||
| Trade and Non-Trade Payables | 3.27M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 540.00K | ||
| Net Cash Flow from Financing | 9.99M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 13.09M | ||
| Issuance (Purchase) of Equity Shares | 47.00K | ||
| Net Cash Flow from Investing | 21.30M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 21.30M | ||
| Net Cash Flow from Operations | -18.21M | ||
| Share Based Compensation | 5.53M | ||